Treatment of recurrent hepatocellular carcinoma: The current standards and future perspectives

Core Tip

Core Tip: Recurrent hepatocellular carcinoma (HCC) is indeed an increasing concern, especially as the global incidence of chronic liver diseases continues to rise. The management of recurrent HCC remains complex, particularly after liver transplantation or hepatic resection, as there is no universally agreed-upon approach. Several treatment modalities are available as locoregional and systemic therapies, and each comes with its own set of advantages and challenges. As recurrent HCC becomes more prevalent, developing a clear, evidence-based treatment approach will be crucial. Further research and prospective randomized trials are essential to determine the best management strategies, establish guidelines, and improve long-term patient outcomes in this challenging clinical scenario.